<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838850</url>
  </required_header>
  <id_info>
    <org_study_id>CS8635-SIT-11-01</org_study_id>
    <nct_id>NCT01838850</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Triple Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg in Patients With Hypertension Not Controlled With Dual Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg and Hydrochlorothiazide 12.5mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CS-8635 combines three widely prescribed antihypertensive medications, olmesartan
      medoxomil(OM), amlodipine (AML), and hydrochlorothiazide (HCTZ), to lower blood pressure. The
      purpose of the study is to evaluate the efficacy and safety of triple therapy with CS-8635
      compared with dual therapy in Korean patients with hypertension not controlled with dual
      fixed dose combination therapy (Olmetec® Plus). The treatments that will be used in this
      study are as follows: Run-in period -OM/HCTZ 20/12.5 mg (Olmetec® Plus 20/12.5 mg) ; Double
      blind treatment period - OM/AML/HCTZ 20/5/12.5mg (CS8635 20/5/12.5mg) + its matching placebo
      vs.OM/HCTZ 20/12.5mg (Olmetec® Plus 20/12.5 mg) + its matching placebo; Open label extension
      period - OM/AML/HCTZ 40/5/12.5mg (CS8635 40/5/12.5mg) or OM/AML/HCTZ 20/5/12.5mg (CS8635
      20/5/12.5mg).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please refer to arms, outcome measures and eligibility criteria for details.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of seated diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg</measure>
    <time_frame>from baseline to week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of mean seated systolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg</measure>
    <time_frame>from baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of mean seated systolic and diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg</measure>
    <time_frame>from baseline to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving blood pressure goal of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg</measure>
    <time_frame>at Week 4, and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving blood pressure goal of the Triple Combinations OM/AML/HCTZ 40/5/12.5mg vs.OM/AML/HCTZ 20/5/12.5mg</measure>
    <time_frame>At week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of mean seated systolic and diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 40/5/12.5mg vs.OM/AML/HCTZ 20/5/12.5mg</measure>
    <time_frame>from Week 8 to Week 16</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Collection of safety data from Adverse event, Laboratory test, Physical examination, Vital signs with pulse and ECG</measure>
    <time_frame>from screening to Week 16</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>CS8635 20/5/12.5mg and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this triple fixed dose combination therapy (CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5mg) + placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 40/5/12.5mg (OM/AML/HCTZ 40/5/12.5 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmetec® Plus 20/12.5mg and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this dual fixed dose combination therapy (Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5mg) + Placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS8635 20/5/12.5mg and placebo</intervention_name>
    <description>Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.
Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.
Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day.</description>
    <arm_group_label>CS8635 20/5/12.5mg and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmetec® Plus 20/12.5mg and placebo</intervention_name>
    <description>Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.
Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.
Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day.</description>
    <arm_group_label>Olmetec® Plus 20/12.5mg and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Screening

          -  Male or female at the age of 20 to 75 years

          -  Voluntary written informed consent to participation in this study

          -  Patients with hypertension either newly diagnosed or without treatment of
             antihypertensive drugs within 4 weeks of screening, who have mean seated diastolic
             blood pressure (msDBP) ≥ 100 mmHg at screening, or

          -  Patients who have been on a stable dose of antihypertensive drugs for at least 4 weeks
             before run-in period and meet the following blood pressure criteria at screening:
             Monotherapy: msDBP ≥ 95 mmHg, or Dual combination therapy: msDBP ≥ 90 mmHg, or Triple
             combination therapy: 70 mmHg ≤ msDBP &lt; 90 mmHg

        Inclusion criteria for randomization

          -  msSBP/DBP at randomization: msSBP ≥ 140 mmHg (msSBP ≥ 130 mmHg in subjects with
             diabetes or chronic renal disease), and msDBP ≥ 90 mmHg (msDBP ≥ 80 mmHg in subjects
             with diabetes or chronic renal disease)

        Exclusion Criteria:

          -  msDBP ≥ 115mmHg or msSBP ≥ 200 mmHg measured at screening and randomization

          -  Patients with mini-max blood pressure difference of SeSBP ≥ 20 mmHg or SeDBP ≥ 10 mmHg
             in the chosen arm at screening

          -  Patients with blood pressure difference of SeSBP ≥ 20 mmHg and SeDBP ≥ 10 mmHg in both
             arms at screening

          -  Patients with hypersensitivity to the investigational product or any of its components

          -  Patients with medical history or hypersensitivity to sulfonamide, dihydropyridine, or
             thiazide diuretics

          -  History of secondary hypertension or history of any of the diseases suspected of
             secondary hypertension

          -  Symptomatic orthostatic hypotension

          -  Uncontrolled diabetes mellitus

          -  Severe heart disease, or ischemic heart disease, peripheral vascular disease

          -  Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter,
             or other arrhythmia considered clinically significant

          -  Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease,
             aortic stenosis, or hemodynamically significant stenosis on aortic valve or mitral
             valve.

          -  Severe cerebrovascular disorder

          -  Known moderate or malignant retinopathy

          -  Consumption disease , autoimmune disease, or connective tissue disease

          -  Patients requiring chronic anti-inflammatory treatment

          -  Anuria or severe renal failure

          -  Severe hepatic failure, AST or ALT &gt; 3 times the upper limit of normal, biliary
             obstruction, biliary cirrhosis, or cholestasis

          -  Patients who have been treated for hyponatremia, hypokalemia, hyperkalemia,
             hypercalcemia, or symptomatic hyperuricemia

          -  Addison's disease

          -  Glucose-galactose malabsorption, galactose intolerance, or Lapp lactase deficiency

          -  Gastrointestinal tract disease or surgical operation that may affect absorption,
             distribution, metabolism, and excretion of drugs, presence of active gastritis or
             gastrointestinal/rectal bleeding considered clinical significant by the investigator,
             active inflammatory bowel syndrome within the last 12 months, etc

          -  Patients with history of or suspected of drug or alcohol abuse

          -  Pregnant or lactating women, or women of childbearing potential who do not agree to
             use appropriate contraceptive methods such as progestin hormone therapy (Oral,
             implant), intrauterine device, barrier methods of contraception (condom or occlusive
             cap (diaphragm or cervical/vault caps) with spermicide), male sterilisation or true
             abstinence

          -  Patients who participated in other clinical study within 1 month prior to screening

          -  Patients considered to be incapable of complying with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Wook Nam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheol-Ho Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Hong Baek</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital of the Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo-Baek Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeouido St. Mary's Hospital of the Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo-Shik Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae-Hoon Ahn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jang-Hyun Cho</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Carollo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung-Hee Oh</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National Univerisity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hweung-Kon Hwang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang-Gyu Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eun-Seok Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Ju Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joon-Han Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung-Ho Jeong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin-Ok Jeong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chong-Jin Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Hospital at Gandong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jang-Ho Bae</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung-Hwan Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonju Severance Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Se-Joong Rim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay-Young Rhew</last_name>
    <role>Principal Investigator</role>
    <affiliation>Presbyterian medical center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Doo-Il Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dae-Kyeong Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soon-Kil Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hye-Sun Seo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Duk-Hyun Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-Dae Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Woon Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taek-Jong Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong-Won Ha</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo-Jung Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Ho Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kee-Sik Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daegu Catholic University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung-Woo Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanmsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wan-Joo Shim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo-Young Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Insurance Service Ilsan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae-Woong Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eulji General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sun-Hwa Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeong-Cheon Ahn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keun Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Veterans Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byung-Soo Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daedong Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <zip>431-796</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital</name>
      <address>
        <city>Bucheon</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daedong Hospital</name>
      <address>
        <city>Busan</city>
        <zip>607-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>612-896</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <zip>361-711,</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Medical Center</name>
      <address>
        <city>Cheonju</city>
        <zip>560-750</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Cheonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>302-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Insurance Service Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri</city>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>405-835</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Hospital at Gandong</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanmsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital of the Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>139-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeouido St. Mary's Hospital of the Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-840</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Carollo Hospital</name>
      <address>
        <city>Suncheon</city>
        <zip>540-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

